Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry
Leukemia and Lymphoma, vol.59, no.1, pp.85-96, 2018 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 59 Issue: 1
- Publication Date: 2018
- Doi Number: 10.1080/10428194.2017.1330472
- Journal Name: Leukemia and Lymphoma
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.85-96
- Keywords: children and adolescents, hematopoietic stem cell transplantation, Relapsed or refractory non-Hodgkin lymphoma
- Ondokuz Mayıs University Affiliated: Yes
Abstract
We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemoresistant disease (69% vs. 37%, p =.019 for OS; 54% vs. 12%, p <.001 for EFS; respectively). A chemoresistant disease at transplantation was the only factor that predicted a limited OS (hazard ratio = 10.00) and EFS (hazard ratio = 16.39) rates. Intensive chemotherapy followed by HSCT could be an effective strategy for treating children with rr-NHL and may offer improved survival for a significant group of pediatric patients, particularly those with chemosensitive disease at transplantation.